Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

[1]  B. Monk,et al.  Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. , 2015, Gynecologic oncology.

[2]  A. Reuss,et al.  Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[4]  A. Oza,et al.  Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials , 2015, Cancer.

[5]  P. Sabbatini,et al.  A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213) , 2015 .

[6]  B. Monk,et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Kosma,et al.  Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer , 2014, BMC Cancer.

[8]  B. Monk,et al.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[9]  B. Monk,et al.  Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer , 2014 .

[10]  J. Haybaeck,et al.  Malignant ascites in ovarian cancer and the role of targeted therapeutics. , 2014, Anticancer research.

[11]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Monk,et al.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. , 2014, Gynecologic oncology.

[13]  N. Colombo.  Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. , 2013, Future oncology.

[14]  B. Monk,et al.  Incidence and management of edema associated with trebananib (AMG 386). , 2013, Gynecologic oncology.

[15]  M. Dimopoulos,et al.  Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer , 2013, International journal of molecular sciences.

[16]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[17]  T. Miner,et al.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. , 2012, World journal of gastrointestinal surgery.

[18]  N. Colombo,et al.  A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. , 2012, Gynecologic oncology.

[19]  D. Provencher,et al.  Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. , 2012, The Lancet. Oncology.

[20]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[22]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[23]  S. Barni,et al.  A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. , 2011, Critical reviews in oncology/hematology.

[24]  Isabelle Barillot,et al.  Évaluation par le patient de la toxicité aiguë de la radiothérapie pelvienne selon la Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0) : rêve ou réalité ? , 2010 .

[25]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[28]  N. Yang,et al.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.

[29]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[30]  J. Udagawa,et al.  Expression of Angiopoietin-1, Angiopoietin-2, and Tie2 Genes in Normal Ovary with Corpus luteum and in Ovarian Cancer , 2002, Oncology.

[31]  Ann-Marie Martoglio,et al.  Changes in Tumorigenesis- and Angiogenesis-related Gene Transcript Abundance Profiles in Ovarian Cancer Detected by Tailored High Density cDNA Arrays , 2000, Molecular medicine.

[32]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[33]  R. Kryscio,et al.  The prognostic implication of ascites in advanced-stage ovarian cancer. , 1996, Gynecologic oncology.

[34]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.